Form 4: Disc Medicine CEO Sells Shares After Option Exercise
Insider Transaction Report
Disc Medicine CEO John D. Quisel exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.
Summary
- John D. Quisel, Chief Executive Officer and Director of Disc Medicine, Inc. (IRON), engaged in transactions involving the company's common stock.
- On December 11, 2025, Mr. Quisel acquired 40,000 shares of common stock by exercising stock options at a price of $9.86 per share.
- Immediately following the option exercise on the same date, Mr. Quisel sold a total of 40,000 shares of common stock in multiple transactions.
- The sales occurred at weighted average prices ranging from $90.973 to $93.6493 per share.
- These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.
- Following these transactions, Mr. Quisel beneficially owns 171,828 shares of common stock and 75,375 stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While insider sales can sometimes be perceived negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns that the sales are based on immediate negative company developments. The transactions represent a planned liquidity event for the executive.
Positives
- The exercise of stock options at a strike price of $9.86, significantly below the market sale prices, indicates a substantial personal gain for the executive.
- The transactions were conducted under a Rule 10b5-1 trading plan, which suggests the sales were pre-scheduled and not based on immediate, non-public information, potentially mitigating negative investor perception.
Negatives
- The sale of 40,000 shares by the CEO, even under a 10b5-1 plan, reduces his direct equity exposure in the company, which some investors might interpret as a lack of conviction or a move towards diversification.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Adoption | The transactions were conducted under a Rule 10b5-1 trading plan adopted on February 13, 2025, which allows insiders to set up a pre-arranged plan to buy or sell company stock. | 02/13/2025 | The use of a 10b5-1 plan enhances transparency and provides an affirmative defense against insider trading allegations, aligning with good corporate governance practices. |
Stakeholder Impact
- Shareholders may view the CEO's sale of shares with mixed reactions; some may see it as a routine diversification or liquidity event under a pre-planned schedule, while others might perceive it as a reduction in insider confidence, potentially influencing short-term stock sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Date Rule 10b5-1 trading plan was adopted. |
| 12/11/2025 | Date of stock option exercise and subsequent common stock sales. |
| 12/15/2025 | Date the Form 4 was signed. |
| 09/13/2031 | Expiration date of the exercised stock options. |
Keywords
Disc Medicine, IRON, Insider Trading, Form 4, Stock Options, CEO, Equity Sales, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.